Ledipasvir/Sofosbuvir, Gilead Sciences

Drug: Ledipasvir/Sofosbuvir
Company: Gilead Sciences
Phase: Filed
Class: Hepatitis C nucleoside NS5A & NS5B polymerase inhibitor
2020 sales: $2.8 billion
Net present value: $9.8 billion

Whatever else is going on at the company, Gilead ($GILD) knows how to make money with new drugs. Loved for its innovation, hated for its pricing, Gilead steamrolled ahead with Sovaldi (sofosbuvir) through the clinic and right into the biggest drug launch of all time. Now comes the first combo for hepatitis C, the next step in a new generation of cocktail therapies that are eradicating the former mainstays in the disease and making it possible for a wide swathe of patients to complete the cure. Gilead grew rhino-thick skin developing the HIV market and it promises to continue its damn-the-torpedoes-full-speed-ahead philosophy in hep C.

For more:
AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck
Gilead hands its hep C combo to the FDA as AbbVie race heats up
Gilead scrambles toward hep C cure-all with next-gen combo pill

Ledipasvir/Sofosbuvir, Gilead Sciences
Read more on

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.